RESUMEN
[Figure: see text].
Asunto(s)
5'-Nucleotidasa/administración & dosificación , Adenosina/metabolismo , Portadores de Fármacos , Miembro Posterior/irrigación sanguínea , Isquemia/tratamiento farmacológico , Maleimidas/química , Enfermedad Arterial Periférica/tratamiento farmacológico , Polietilenglicoles/química , 5'-Nucleotidasa/química , 5'-Nucleotidasa/metabolismo , Animales , Células Cultivadas , Preparaciones de Acción Retardada , Modelos Animales de Enfermedad , Composición de Medicamentos , Femenino , Humanos , Hidrogeles , Isquemia/enzimología , Isquemia/fisiopatología , Masculino , Ratones Endogámicos C57BL , Activación Neutrófila/efectos de los fármacos , Enfermedad Arterial Periférica/enzimología , Enfermedad Arterial Periférica/fisiopatología , Flujo Sanguíneo Regional , Regulación hacia ArribaRESUMEN
A total of 58 patients with ischemic heart disease and angina of effort (FC II) (mean age 55.6 years) participating in the study were diagnosed to have erective dysfunction (ED) of a mild (35%), moderate (57%) and severe degree (8%). All the patients were randomized into two groups. Group 1 (n=21, mean age 56.4 years) received standard cardiotropic therapy (nitrates, beta-blockers, ACE inhibitors on demand, diuretics, antioxidants) and placebo. Group 2 (n=37, mean age 54.3 years) received the same standard cardiotropic therapy plus impase (1 tablet each other day for 3 months). The results of the trial show that impase addition to cardiotropic therapy raised exercise tolerance, diminished the number of anginal attacks in mild and moderate exercise, enhanced coronary microcirculatory blood flow, increased reserve circulation index by 34%, improved metabolism of vascular endothelium in the whole body. Impase acts pathogenetically in endothelial insufficiency. Prevention of endothelial dysfunction by impase allows both to stop progression of cardiovascular disease and to prevent erectile dysfunction.
Asunto(s)
Disfunción Eréctil/tratamiento farmacológico , Isquemia Miocárdica/tratamiento farmacológico , 5'-Nucleotidasa/administración & dosificación , Antagonistas Adrenérgicos beta/administración & dosificación , Inhibidores de la Enzima Convertidora de Angiotensina/administración & dosificación , Antioxidantes/administración & dosificación , Circulación Coronaria/efectos de los fármacos , Diuréticos/administración & dosificación , Endotelio Vascular/metabolismo , Endotelio Vascular/patología , Disfunción Eréctil/complicaciones , Disfunción Eréctil/metabolismo , Disfunción Eréctil/patología , Ejercicio Físico , Humanos , Masculino , Persona de Mediana Edad , Isquemia Miocárdica/complicaciones , Isquemia Miocárdica/metabolismo , Isquemia Miocárdica/patología , Nitratos/administración & dosificaciónRESUMEN
Efficacy of impasse in therapy of sexual dysfunctions of vascular genesis was studied in 38 male patients aged 35-68 years. The drug was taken for 2 months. The control was conducted with ultrasonic dopplerography. Impasse showed high efficacy in therapy of vascular sexual dysfunctions especially in the group of patients aged 35-50 years with initial values of maximal systolic speed at least 15 cm/s.
Asunto(s)
5'-Nucleotidasa/uso terapéutico , Disfunción Eréctil/tratamiento farmacológico , Pene/irrigación sanguínea , 5'-Nucleotidasa/administración & dosificación , Adulto , Factores de Edad , Anciano , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Esquema de Medicación , Disfunción Eréctil/etiología , Disfunción Eréctil/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Pene/efectos de los fármacos , Resultado del TratamientoRESUMEN
Though the potential use of adenosine as a neuroprotective agent has long been realized, there are currently no adenosine-based therapies for the prevention or treatment of cerebral ischemia and reperfusion injury. Prostatic acid phosphatase (PAP), an enzyme that has long served as a diagnostic marker for prostate cancer, has been recently demonstrated to exhibit ecto-5'-nucleotidase activity, and dephosphorylate endogenous extracellular AMP to adenosine. We therefore tested the hypothesis that PAP has sustained and potent neuroprotective effects against cerebral ischemia in the rat model of middle cerebral artery occlusion. We found that hPAP produced significant neuroprotection against focal cerebral ischemia, as evident from significant reduction in cerebral infarction and neurological deficits. The therapeutic time window for hPAP in rat focal cerebral ischemia model was limited from 6 h before ischemia to 1.5 h after reperfusion. The present study suggested that PAP is a potential candidate for the prevention and treatment of cerebral ischemic injury, especially during perioperative period.